juvenile idiopathic arthritis
Rheumatology · 2011–2025
11decisions
4medicines
4carried consumer input
18individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Treatment of immune-mediated inflammatory diseases (IMIDs) in paediatric patients under 18 years of age, with disease severity considered sufficient to cause… | Jul 2025 | Recommended with restriction | 6 individuals |
| etanercept Severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2025 | Recommended with restriction | none received |
| tofacitinib Treatment of severe active juvenile idiopathic arthritis (JIA) in patients aged 2-17 years with polyarticular course JIA who have not achieved adequate… | Mar 2023 | Recommended with restriction | 11 individuals Australian Rheumatology Association · Arthritis Australia · Musculoskeletal Australia · Creaky Joints Australia · Juvenile Arthritis Foundation Australia · Pain Australia |
| etanercept Listing of etanercept injection 50 mg in 1 mL single use dose-dispenser cartridges for the same indications as currently listed etanercept pre-filled syringes:… | Jul 2021 | Recommended with restriction | unclear |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile idiopathic arthritis. | Nov 2021 | Recommended | unclear |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| adalimumab Multiple indications including severe Crohn's disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, fistulising Crohn's… | Jul 2018 | Recommended with restriction | none received |
| etanercept Biosimilar etanercept for multiple indications including severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic… | Mar 2018 | Recommended with restriction | none received |
| etanercept Biosimilar to etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended | input received |
| etanercept Treatment of severe active juvenile idiopathic arthritis in patients under 18 years of age who have a body weight of 62.5 kg or greater. | Jul 2014 | Recommended with restriction | no section in document |
| Abatacept Treatment of severe active juvenile idiopathic arthritis (JIA) in patients who have severe intolerance of, or toxicity due to methotrexate or who have failed… | Jul 2011 | Deferred | no section in document |
Who spoke
Australian Rheumatology Association · Arthritis Australia · Musculoskeletal Australia · Creaky Joints Australia · Juvenile Arthritis Foundation Australia · Pain Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 10 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.